JSM 2004 - Toronto

JSM Activity #29

This is the preliminary program for the 2004 Joint Statistical Meetings in Toronto, Canada. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 7-10, 2004); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2004 Program page
Legend: = Applied Session, = Theme Session, = Presenter
FRY = Fairmont Royal York, ICH = InterContinental Hotel, TCC = Metro Toronto Convention Center
Add To My Program
29 Theme Session Sun, 8/8/04, 2:00 PM - 3:50 PM TCC-718 B
Clinical Trials - Contributed - Papers
Biopharmaceutical Section
Chair(s): Gary Aras, Amgen, Inc.
     2:05 PM   Impact on Error Rates When Futility Criteria is Based on Secondary Endpoint — Akiko Okamoto, Johnson & Johnson Pharmaceutical R&D, LLC; Yi-wen Ma, Johnson & Johnson Pharmaceutical R&D, LLC; Surya Mohanty, Johnson & Johnson Pharmaceutical R&D, LLC
     2:20 PM   The Application of Enhanced Parallel Gatekeeping Strategies — Xun Chen, Merck & Co., Inc.; Edmund Luo, Merck & Co., Inc.; Thomas Capizzi, Merck & Co., Inc.
     2:35 PM   Fallback and Gatekeeping Strategies for Primary and Secondary Endpoints — Brian L. Wiens, Amgen, Inc.; Alexei Dmitrienko, Eli Lilly and Company; Peter H. Westfall, Texas Tech University
     2:50 PM   Application of Statistical Sampling Principles to Clinical Trial Management — Guy Cohen, Pfizer Inc.; Cynthia Siu, Roche Pharmaceuticals; Isma Benattia, Wyeth Pharmaceuticals; Darryl Penenberg, Pfizer Pharmaceuticals; Vito Calamia, Pfizer Pharmaceuticals; Joan Rex, Wyeth Pharmaceuticals; Christine Clemente, Pfizer Pharmaceuticals
     3:05 PM   A Case Study of a Group-sequential Response Adaptive Clinical Trial — Roy Tamura, Eli Lilly and Company; Janelle Erickson, Eli Lilly and Company
     3:20 PM   On Statistical Properties of QT Correction Methods — Yibin Wang, Novartis Pharmaceuticals; Guohua Pan, Johnson & Johnson Pharmaceutical R&D, LLC; Alfred Balch, Novartis Pharmaceuticals
     3:35 PM   The Growing Role of the Biostatistician in Safety Assessment of Clinical Trials for Regulatory Approval — Michael Nessly, Merck & Co., Inc.
 

JSM 2004 For information, contact jsm@amstat.org or phone (888) 231-3473. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2004